tiprankstipranks
Trending News
More News >
Rion Co., Ltd. (JP:6823)
:6823
Japanese Market
Advertisement

Rion Co., Ltd. (6823) AI Stock Analysis

Compare
0 Followers

Top Page

JP:6823

Rion Co., Ltd.

(6823)

Select Model
Select Model
Select Model
Neutral 69 (OpenAI - 4o)
Rating:69Neutral
Price Target:
¥2,875.00
▲(9.36% Upside)
Rion Co., Ltd. has a strong financial foundation with robust revenue growth and cash flow generation. However, technical indicators suggest short-term bearish momentum, which tempers the overall score. The stock is reasonably valued with an attractive dividend yield, making it a balanced investment opportunity.

Rion Co., Ltd. (6823) vs. iShares MSCI Japan ETF (EWJ)

Rion Co., Ltd. Business Overview & Revenue Model

Company DescriptionRion Co., Ltd. manufactures, sells, and maintains hearing instruments, medical equipment, sound and vibration measuring instruments, particle counters, and related parts and equipment in Japan. The company's audiological equipment includes hearing instruments, such as analog and digital BTE, trimmer digital BTE, in-the-ear ready and custom made, and analog body aid instruments, as well as waterproof hearing instruments; and medical equipment comprising audiometers and OAE screeners. Its sound and vibration measuring instruments include sound level meters, vibration meters, seismometers, frequency analyzers, microphones and accelerometers, recorders, and other products. The company's particle counters comprise air and liquid- borne particle counters, and viable particle counters. Its products are primarily used in the applications of environment-related administration, electronics, semiconductors, pharmaceutical, and food manufacturing industries. The company was formerly known as Kobayashi-Riken Seisakusho Ltd. and changed its name to Rion Co., Ltd. in 1960. Rion Co., Ltd. was incorporated in 1944 and is headquartered in Kokubunji, Japan.
How the Company Makes MoneyRion Co., Ltd. generates revenue through the sale of its medical devices and scientific instruments. The company earns significant income from its hearing aid division, which includes both sales and service revenues. Additionally, Rion benefits from government contracts and collaborations with healthcare institutions for diagnostic equipment. The company also invests in research and development to innovate and expand its product offerings, which further supports its revenue growth. Strategic partnerships with healthcare providers and distribution networks enhance its market reach and contribute to its earnings.

Rion Co., Ltd. Financial Statement Overview

Summary
Rion Co., Ltd. exhibits strong financial performance with impressive revenue growth and stable profitability. The balance sheet is robust with low leverage and efficient equity utilization. The cash flow statement highlights strong cash generation and improved free cash flow, positioning the company well for future growth.
Income Statement
85
Very Positive
Rion Co., Ltd. has demonstrated strong revenue growth with a 61% increase in the latest year, indicating robust demand for its products. The gross profit margin remains healthy at approximately 50%, although it has slightly decreased from the previous year. The net profit margin is stable at around 10%, reflecting consistent profitability. EBIT and EBITDA margins are solid, showcasing effective cost management and operational efficiency.
Balance Sheet
78
Positive
The company's balance sheet is strong with a very low debt-to-equity ratio, indicating minimal leverage and financial risk. Return on equity is stable at around 9%, suggesting efficient use of shareholder funds. The equity ratio is healthy, reflecting a solid capital structure. Overall, the balance sheet portrays financial stability and low risk.
Cash Flow
80
Positive
Rion Co., Ltd. has shown significant improvement in free cash flow, with a notable growth rate. The operating cash flow to net income ratio is strong, indicating good cash generation relative to net income. The free cash flow to net income ratio has improved significantly, reflecting enhanced cash flow efficiency. Overall, the cash flow statement indicates strong cash generation and financial flexibility.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue27.88B27.88B25.73B23.87B22.64B20.47B
Gross Profit14.03B13.99B14.33B11.70B11.38B10.23B
EBITDA5.07B5.14B4.42B3.13B3.89B3.16B
Net Income2.86B2.86B2.65B1.80B2.23B1.64B
Balance Sheet
Total Assets39.13B39.13B37.14B34.56B33.16B30.68B
Cash, Cash Equivalents and Short-Term Investments6.01B6.01B5.03B5.37B7.72B6.44B
Total Debt11.73M11.73M21.88M28.46M40.07M52.95M
Total Liabilities7.70B7.70B7.93B7.95B7.87B6.96B
Stockholders Equity31.44B31.44B29.21B26.61B25.29B23.73B
Cash Flow
Free Cash Flow0.002.14B166.61M-279.14M1.76B943.08M
Operating Cash Flow0.003.44B2.86B1.78B2.84B2.06B
Investing Cash Flow0.00-1.69B-2.65B-3.25B-951.93M-1.14B
Financing Cash Flow0.00-748.84M-565.55M-577.32M-541.83M-566.42M

Rion Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2629.00
Price Trends
50DMA
2638.98
Positive
100DMA
2542.07
Positive
200DMA
2508.71
Positive
Market Momentum
MACD
-0.03
Positive
RSI
52.78
Neutral
STOCH
62.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6823, the sentiment is Positive. The current price of 2629 is below the 20-day moving average (MA) of 2658.70, below the 50-day MA of 2638.98, and above the 200-day MA of 2508.71, indicating a bullish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 52.78 is Neutral, neither overbought nor oversold. The STOCH value of 62.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:6823.

Rion Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
285.39B21.157.85%1.81%4.43%-1.39%
74
Outperform
17.47B16.920.00%3.32%-8.07%-38.21%
69
Neutral
¥32.42B10.73
2.44%7.99%28.81%
66
Neutral
128.50B11.338.21%4.14%0.70%0.00%
63
Neutral
78.28B35.455.11%2.16%3.80%6.68%
54
Neutral
40.88B-119.03-0.85%-5.24%81.24%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:6823
Rion Co., Ltd.
2,659.00
641.78
31.82%
CYBQF
CYBERDYNE
1.30
-0.09
-6.47%
DE:2GY
PHC Holdings Corp.
5.75
-0.74
-11.40%
JP:4549
Eiken Chemical Co., Ltd.
2,464.00
136.68
5.87%
JP:6678
Techno Medica Co., Ltd.
2,065.00
201.94
10.84%
JP:6849
Nihon Kohden Corporation
1,732.00
-292.04
-14.43%

Rion Co., Ltd. Corporate Events

Rion Co., Ltd. Announces Key Personnel Change
Apr 21, 2025

Rion Co., Ltd. announced a personnel change with the appointment of Shinya Ejima as a new independent outside director, replacing Motonori Tuno, who is retiring. This change is set to be proposed at the upcoming Annual General Meeting, potentially impacting the company’s strategic direction with Ejima’s extensive experience in international cooperation and management.

Rion Co., Ltd. Reports Strong Nine-Month Financial Performance and Announces Revised Dividend Forecast
Feb 6, 2025

Rion Co., Ltd. reported a positive financial performance for the first nine months of the fiscal year ending March 31, 2025, with a notable increase in net sales and operating profit compared to the previous year. The company also announced a revised dividend forecast, indicating confidence in its financial stability and commitment to rewarding shareholders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 05, 2025